281
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

PALB2 variant status in hematological malignancies – a potential therapeutic target?

ORCID Icon, , ORCID Icon, , , , , ORCID Icon, , ORCID Icon, ORCID Icon, , , , , ORCID Icon, & ORCID Icon show all
Pages 1823-1826 | Received 16 Aug 2018, Accepted 18 Nov 2018, Published online: 07 Jan 2019

References

  • Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA. 2009;106:7155–7160.
  • Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159–161.
  • Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162–164.
  • Byrd PJ, Stewart GS, Smith A, et al. A hypomorphic PALB2 allele gives rise to an unusual form of FA-N associated with lymphoid tumour development. PLoS Genet. 2016;12:e1005945.
  • Sayers EW, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2012;40:D13–D25.
  • Foo TK, Tischkowitz M, Simhadri S, et al. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. Oncogene. 2017;36:4161–4170.
  • Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012;97:142–146.
  • Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714–726.
  • Blanco A, de la Hoya M, Osorio A, et al. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases. PLoS One. 2013; 8:e67538.
  • Downs B, Kim YC, Xiao F, et al. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer. Breast Cancer Res Treat. 2015;151:219–224.
  • Stankovic T, Stewart GS, Byrd P, et al. ATM mutations in sporadic lymphoid tumours. Leuk Lymphoma. 2002;43:1563–1571.
  • Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014;30:326–339.
  • Pearl LH, Schierz AC, Ward SE, et al. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015;15:166–180.
  • O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547–560.
  • Murphy AK, Fitzgerald M, Ro T, et al. Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. J Cell Biol. 2014;206:493–507.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.